Author

K. M. Keller

Princess Máxima Center

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Research Focus:cell type annotation· 2 Organism:mouse· 2 Assay:proteomics· 2 Assay:scRNA-seq· 2 Research Focus:differential expression· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. B. P. van KuilenburgiD· 1 shared A. Eggermont· 1 shared A. J. R. Heck· 1 shared A. Louwagie· 1 shared A. M. Cornel· 1 shared A. Rodriguez· 1 shared A. Sanchez-Bernabeu· 1 shared Arjan BoltjesiD· 1 shared

Activity by Year

2020-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 13 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. B. P. van KuilenburgORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Metastatic tumor cells in bone marrow differ from paired neuroblastoma tumor and contain subsets with therapy-resistant characteristics

Caroline Hochheuser, Arjan Boltjes, K. M. Keller, Simon Tol, M. van de Mheen, C. Pita Barros, Zeinab van Gestel-Fadaie, A. B. P. van Kuilenburg, Sander R. van Hooff, Carlijn Voermans, Jan J. Molenaar, Godelieve A.M. Tytgat, Ilse Timmerman

EJC Paediatric Oncology · Mar 25, 2026Peer-reviewedCancer Biology

Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy

J. Wienke, L. L. Visser, W. M. Kholosy, K. M. Keller, M. Barisa, S. Munnings-Tomes, E. Carlton, E. Poon, A. Rodriguez, R. Bernardi, F. Van den Ham, S. R. Van Hooff, Y. A. H. Matser, M. Tas, K. P. S. Langenberg, , J. J Molenaar

The paper uses single-cell RNA sequencing to analyze neuroblastoma and identifies the NECTIN2-TIGIT axis as a potential target for immunotherapy.

bioRxiv · Jul 15, 2022Cancer Biology

RRM2 is a target for synthetic lethal interactions with replication stress checkpoint addiction in high-risk neuroblastoma

C. Nunes, L. Depestel, L. M. Mus, K. M. Keller, L. Delhaye, A. Louwagie, M. Rishfi, E. M. Dolman, V. Olexiouk, C. Bartenhagen, F. Devloed, E. Sanders, A. Eggermont, J. Van Laere, E. De Smet, , F. Speleman

This study identifies RRM2 as a therapeutic target in high-risk neuroblastoma, showing that combined RRM2 and CHK1 inhibition synergistically reduces tumor growth.

bioRxiv · Nov 25, 2020 · PreprintCancer Biology